The total return over the past 12 months is -49.83% vs. +16.94% for the S&P 500. So far it's up 0.00% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (70.94%) | (73.06%) | (63.51%) | (57.08%) | (58.30%) | (58.92%) |
| Total Return CAGR | (49.83%) | (69.12%) | (60.51%) | (55.35%) | (57.19%) | (58.10%) |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cellectar Biosciences, Inc. (CLRB)
| Year | Start price | End price | CLRB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.95 | $1.67 | 0.00% | +14.51% | (14.51%) |
| 2025 | $8.97 | $2.95 | (75.00%) | +17.72% | (92.72%) |
| 2024 | $83.10 | $8.97 | (88.24%) | +24.89% | (113.13%) |
| 2023 | $51.30 | $83.10 | +61.90% | +26.19% | +35.71% |
| 2022 | $198.00 | $51.30 | (73.75%) | (18.17%) | (55.58%) |
| 2021 | $624.00 | $198.00 | (68.25%) | +28.74% | (96.99%) |
| 2020 | $675.00 | $624.00 | (7.35%) | +18.37% | (25.72%) |
| 2019 | $465.00 | $675.00 | +44.68% | +31.22% | +13.46% |
| 2018 | $4,110.00 | $465.00 | (88.66%) | (4.56%) | (84.10%) |
| 2017 | $3,660.00 | $4,110.00 | +12.25% | +21.70% | (9.45%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
